Trad Chi Med (TRAD CHI MED) released its interim report as of June 30, 2024. The report shows that the company's total revenue increased from 9.3 billion yuan in the previous year to approximately 8.385 billion yuan, with a growth rate of 9.9%. However, net profit decreased from 0.881 billion yuan in the previous year to 0.754 billion yuan, a decrease of 14.3%. Operating profit increased from 1.305 billion yuan in the previous year to 1.577 billion yuan, a growth of 20.8%. Total assets decreased from 4.931 billion yuan in the previous year to 3.48 billion yuan, a decrease of 29.4%. The company's total liabilities increased from 2.034 billion yuan to 2.418 billion yuan, an increase of 18.9%. In addition, the report also mentioned the company's ESG performance and future development strategy. Trad Chi Med's operating performance during the reporting period showed stable growth, but the decrease in net profit may attract investors' attention.

Trad Chi Med (TRAD CHI MED) released its interim report as of June 30, 2024. The report shows that the company's total revenue increased from 9.3 billion yuan in the previous year to approximately 8.385 billion yuan, with a growth rate of 9.9%. However, net profit decreased from 0.881 billion yuan in the previous year to 0.754 billion yuan, a decrease of 14.3%. Operating profit increased from 1.305 billion yuan in the previous year to 1.577 billion yuan, a growth of 20.8%. Total assets decreased from 4.931 billion yuan in the previous year to 3.48 billion yuan, a decrease of 29.4%. The company's total liabilities increased from 2.034 billion yuan to 2.418 billion yuan, an increase of 18.9%. In addition, the report also mentioned the company's ESG performance and future development strategy. Trad Chi Med's operating performance during the reporting period showed stable growth, but the decrease in net profit may attract investors' attention.